May 29, 2026 | Read online

Morning Check-In: See Why (NASDAQ: GTBP) is the One to Watch Today

Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored

Market Maven Insights Puts (NASDAQ: GTBP) #1 On Today’s Watchlist—Thursday, May 29, 2026

Don’t miss the next breakout — get real-time alerts sent straight to your phone!

Full Coverage On (GTBP) Starts Now

Start Tracking (GTBP) While It’s Still Early…

May 29, 2026
Morning Check-In: See Why (NASDAQ: GTBP) is the One to Watch Today

Dear Reader,

Sometimes the most interesting biotech stories begin attracting attention long before major clinical data arrives.

That appears to be what may be unfolding with GT Biopharma, Inc. (Nasdaq: GTBP), a little-known clinical-stage company that continues advancing multiple oncology programs while quietly building momentum behind the scenes.

The company is developing a proprietary NK cell engager platform designed to activate the body's natural killer cells directly in vivo, with active Phase 1 studies now underway across both hematologic malignancies and solid tumors.

Following recent first-patient dosing in the GTB-5550 basket study, anticipated clinical updates later this year, and a projected cash runway extending into Q4 2026, (GTBP) has rapidly moved to the top of the Market Maven Insights watchlist this morning—Friday, May 29, 2026.

The market has already started taking notice.

(GTBP) was near $0.27 on April 29 and reached approximately $0.48 on May 22, representing an approximate 77% move in less than one month, according to Barchart.

What makes the story increasingly difficult to ignore is the combination of active clinical development, upcoming milestones, and a differentiated platform targeting several difficult-to-treat can-cers.

With two clinical-stage programs already underway and additional milestones expected throughout the year, (GTBP) is emerging as one of the more closely watched biotech stories heading into Friday's session.

The Clinical-Stage Oncology Platform Behind (GTBP)'s Growing Pipeline

GT Biopharma, Inc. (Nasdaq: GTBP), is a clinical-stage immuno-oncology company focused on developing next-generation cancer therapies built around its proprietary TriKE® (Tri-Specific Killer Engager) platform. The technology is designed to activate and expand the body's natural killer (NK) cells, a critical component of the immune system capable of identifying and destroying cancer cells.

The company's lead clinical programs include GTB-3650, currently in an ongoing Phase 1 study targeting relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), and GTB-5550, a B7-H3-targeted NK cell engager that recently entered Phase 1 testing for multiple solid tumor indications.

A major recent milestone occurred when (GTBP) announced the first patient had been dosed in its GTB-5550 Phase 1 basket trial, expanding the TriKE® platform into solid tumors including prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic, and bladder cancers.

Management has stated that current ca-sh resources are expected to fund operations through the fourth quarter of 2026 while enrollment and dose-escalation activities continue across both clinical programs. The company expects to provide additional clinical updates during the second half of 2026.

Today, (GTBP) is positioning its TriKE® platform across both hematologic malignancies and solid tumors, creating exposure to multiple oncology indications while advancing a pipeline centered on NK cell-based immunotherapy.

Growing Demand For Next-Generation Cancer Immunotherapies

The global cancer immunotherapy market was valued at approximately $136B in 2025 and is projected to reach roughly $367B by 2035, reflecting an estimated 10.4% CAGR.

Within that market, NK cell therapeutics are expected to grow from approximately $3.2B in 2024 to $8.6B by 2033.

(GTBP)'s GTB-5550 program is targeting a portion of the estimated $362B global solid tumor market and is currently being evaluated across multiple B7-H3-expressing cancers, including prostate, ovarian, breast, lung, pancreatic, bladder, and head and neck tumors.

Another point worth noting is growing industry interest in NK cell engager technologies. According to (GTBP)'s May 2026 corporate presentation, major pharmaceutical companies including Sanofi and Gilead have completed NK cell engager transactions with total deal values exceeding $1B.

As demand for next-generation immunotherapies continues expanding, NK cell-based approaches remain an area attracting increasing industry attention.

Recent Milestones Driving Attention Toward (GTBP)

First Patient Dosed In GTB-5550 Phase 1 Trial: (GTBP) announced the first patient had been dosed in its Phase 1 basket study evaluating GTB-5550, a B7-H3-targeted NK cell engager for solid tumors. The trial marks the company's expansion into multiple solid tumor indications and management expects additional updates during the second half of 2026.

Expansion Into Solid Tumors: GTB-5550 is now the third TriKE® candidate to enter the clinic and is being evaluated across multiple B7-H3-expressing cancers, including prostate, ovarian, breast, head and neck, lung, pancreatic, and bladder cancers.

Phase 1 GTB-3650 Program Continues Advancing: The company's GTB-3650 study remains active in relapsed/refractory AML and other CD33-positive hematologic malignancies. Prior updates reported successful progression through multiple dose-escalation cohorts with favorable safety observations and biomarker activity.

Runway Extended Into Q4 2026: In its first-quarter 2026 financial results, management stated that existing cash resources are expected to fund operations through the fourth quarter of 2026, supporting ongoing enrollment and clinical development activities.

Additional Clinical Updates Expected: Management has indicated that enrollment and dose-escalation activities remain underway, with additional GTB-5550 and GTB-3650 clinical updates anticipated later in 2026.

7 Reasons Why (GTBP) Is On Our Radar This Morning — Friday, May 29, 2026

1. Micro-Cap Profile: (GTBP) continues to operate with a market capitalization below approximately $20M.

2. Strong Recent Action: Shares advanced approximately 77% from late April to late May, according to Barchart data.

3. First Patient Dosed: The company recently announced first-patient dosing in the GTB-5550 Phase 1 solid tumor study.

4. Two Active Clinical Programs: (GTBP) is currently advancing both GTB-5550 and GTB-3650 through ongoing clinical development.

5. Additional Data Ahead: Management expects further clinical updates during the second half of 2026.

6. Cash Runway Into Q4: Current resources are expected to support operations through the fourth quarter of 2026.

7. Broad TriKE® Platform: The company's pipeline spans hematologic malignancies, solid tumors, and autoimmune disease candidates.

Take A Look At (GTBP) This Morning While It’s Still Early…

With first-patient dosing now underway in GTB-5550, an active Phase 1 study continuing for GTB-3650, additional clinical updates expected later this year, and funding projected into Q4 2026, (GTBP) appears to be entering a period where several milestones are beginning to converge.

At the same time, the company's TriKE® platform provides exposure across both hematologic malignancies and solid tumors, creating multiple pathways for future development.

When those factors are viewed alongside a market capitalization below approximately $20M, (GTBP) stands out as a clinical-stage biotech worth keeping on the radar.

We'll be watching (GTBP) closely throughout today's session.

Take a closer look while the story remains underfollowed.

And keep an eye on your inbox—our next update could arrive at any moment.

Sincerely,
Tate Remington
Chief Editor, Market Maven Insights

^{MarketMavenInsights.com}^{(“MarketMavenInsights” or “MMI”) is owned by Source Coastal Media LLC, a multi member limited liability company. Data is provided from third-party sources and MMI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MMI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors.}

^{Pursuant to an agreement between Source Coastal Media LLC and TD Media LLC, Source Coastal Media LLC has been hired for a period beginning on 05/29/2026 and ending on 05/29/2026 to publicly disseminate information about (GTBP:US) via digital communications. Under this agreement, TD Media LLC has paid Source Coastal Media LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Source Coastal Media LLC has been paid twenty two thousand five hundred USD (“Funds”). These Funds were part of the one hundred thousand USD funds that TD Media LLC received from GT Biopharma Inc., the issuer of (GTBP:US).}

^{Neither Source Coastal Media LLC, TD Media LLC and their member own shares of (GTBP:US).}

^{Please see important disclosure information here:}^{https://marketmaveninsights.com/disclosure/gtbp-2B4ek/#details}